Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,101
datasets available to search
ShareScore release 0.7.1
Dataset results
2,101 results for “Cohort studies”
Data for "Incidence, clinical course and risk factor for recurrent PCR positivity in discharged COVID-19 patients in Guangzhou, China: a prospective cohort study"
<p>Data for "Incidence, clinical course and risk factor for recurrent PCR positivity in discharged COVID-19 patients in Guangzhou, China: a prospective cohort study"</p>
Data for Are Changes in Alcohol Use and Personality Traits associated? A Cohort Study among Young Swiss Men
<p>These are the data and metadata for the article </p> <p><strong>Are Changes in Alcohol Use and Personality Traits associated? A Cohort Study among Young Swiss Men</strong></p> <p>by </p> <p><strong>Gerhard Gmel, Simon Marmet, Joseph Studer, and Matthias Wicki</strong></p> <p><strong>to be published in Frontiers of Psychiatry</strong></p>
Prospective with historical control, case-matched cohort study of the tertiary survey beneficial in critically severe trauma patients.
<p>Raw data, Tertiary survey record form, and STROBE checklist of "Prospective with historical control, case-matched cohort study of the tertiary survey beneficial in critically severe trauma patients" study.</p>
Mental health, physical health, training load and subjective performance during the COVID-19 pandemic – a Swiss elite athletes' cohort study
<p>Dataset of Swiss elite athletes (n=203) participating in a repeated online survey evaluating mental and physical health factors, as well as training and performance related metrics. After the first survey during the first lockdown between April and May 2020, there were monthly follow-up surveys over a 6-month period.</p>
Audio recordings of COVID-19 positive individuals from the prospective Predi-COVID cohort study with their fatigue status
<p>We uploaded <strong>3544 </strong>audio recordings originating from <strong>296 </strong>distinct participants with COVID-19 in the prospective <strong>Predi-COVID cohort study</strong> recruited between May 2020 and May 2021. The audios have been converted from their original format into WAV files and normalized. The audio name structure integrates the participant ID, the recording date and time of the audio recording, the type of audio (Type 1: text reading, Type2: holding the [a] vowel without breathing), the original audio format, the gender (W: women, M: Men), and the <strong>fatigue status</strong> of the participant (1: Fatigue, 0: No fatigue) as such:</p> <p>Predi-COVID_{participant ID}{recording date and time}{type of audio}{original format}{gender}{fatigue status}.wav</p>
Molecular Signatures of Tumour and its Microenvironment for Precise Quantitative Diagnosis of Oral Squamous Cell Carcinoma: An Interna-tional Multi-cohort Diagnostic Validation Study
<p><strong>Supplementary Materials: </strong>The following supporting information can be downloaded at: www.mdpi.com/xxx/s1, <strong>Table ST1</strong> – qMIDS<sup>V2 </sup>Gene panel primer sequences; <strong>Figure S1</strong> – qMIDS<sup>V1</sup> vs qMIDS<sup>V2</sup> 384-well assay format and protocols; <strong>Figure S2.</strong> Individual target gene expression pattern in 1761 samples; <strong>Figure S3.</strong> Various statistical methods used for gene selection analysis on 1761 clinical samples; <strong>Figure S4. </strong>Diagnostic performance comparison between qMIDS<sup>V2</sup> vs qMIDS<sup>V2* </sup>(with 4 less effective genes removed from the panel of 14 target genes of qMIDS<sup>V2</sup>); <strong>Figure S5</strong>. Effect of removing individual genes from the 14-target gene panel qMIDS<sup>V2</sup> (qV2) on diagnostic test performance based on the UK patient cohort data.</p>
ICU post- discharge persistent symptoms, self-reported health and quality of life of COVID-19 survivors: A cohort study.
<p> </p> <p>Understanding the consequences and health impact of COVID-19 survivors discharged from the ICU is still unclear. The aim of this study was to investigated persistent symptoms, health satisfaction and health related quality of life (HRQoL) of patients that were hospitalized due COVID-19 infection after 30, 90 and 180 days from ICU discharge. This is a multicentric prospective cohort study of COVID-19 survivors discharged from 8 hospitals of Curitiba – Paraná (Brazil), between September 2020 and January 2022. Eligible COVID 19 survivors were contacted by phone and invited to answer telephone survey at 30, 90 and 180 days after ICU discharge. They responded a phone questionnaire to collect post-discharge clinical symptoms, and we also asked about health satisfaction and HRQoL. 62 COVID-19 survivors (51,6% males, mean age 50,3 years, median length of ICU stay of 13 days) responded to the telephone survey at 30, 90 and 180 days. The most persistent symptoms were fatigue (65,9%, 51,3%, 44,7%, respectively), mild dyspnea (42%, 31%, 29,8%, respectively) and myalgia (29%, 22,1%, 17%, respectively). Myalgia showed a significant reduction from 30 days to 180 days (p=0,034), and the number of symptoms also reduced significantly (30 to 90 days, <em>p=0.018</em>, 30 to 180 days<em>, p=0.001 </em>). At 30, 90 and 180 follow up days the most patients had reported “good” quality of life (59,7%, 62,9%, 51,6%, respectively), and “satisfied” with health (43,5%, 48,4%, 46,8%, respectively). We found that COVID-19 symptoms persist to 180 days, fatigue more commonly. Nevertheless, in this cohort study, most COVID-19 survivors reported good quality of life and were satisfied with health.</p>
Dataset Validation of seven type 2 diabetes mellitus risk scores in a population-based cohort. The CoLaus Study
<p>This dataset is related to "Validation of seven type 2 diabetes mellitus risk scores in a population-based cohort. The CoLaus Study".</p> <p>Vanessa Kraege*, Janko Fabecic*, Pedro Marques Vidal, Gérard Waeber and Marie Méan</p> <p>*Contributed equally; co-first authors</p>
Data analysis of an LC-MS dataset from a human urine biofluid cohort study
<p>Supplementary dataset and tutorials for the "<strong>Statistical analysis in metabolic phenotyping"</strong></p> <p> </p> <p>This repository contains Jupyter Notebooks with two examplar metabolomic data analysis workflows, applied to a liquid chromatography mass spectrometry dataset (LC-MS). The LC-MS dataset used comes from a metabolic phenotyping investigation of human urine biofluid samples from a dementia cohort. In this sample set, baseline spot urine samples (first sample collected after recruitment to the study) were collected as part of the AddNeuroMed<sup>1</sup> and ART/DCR study consortia, with the aim of identifying biomarkers of neurocognitive decline and Alzheimer’s disease. These samples were analysed by LC-MS and <sup>1</sup>H NMR, using the methods described by Lewis <em>et al</em><sup>2</sup> and Dona <em>et al</em>. Detailed information about this cohort and other available phenotypic measurements can be found in Lovestone and the ANMERGE<sup>3</sup> repository, which can be accessed via the Sage BioNetworks portal (<a href="https://doi.org/10.7303/syn22252881">https://doi.org/10.7303/syn22252881</a>). Information about the metabolic profiling experiments can be found in the study's MetaboLights entry: <a href="https://www.ebi.ac.uk/metabolights/MTBLS719">https://www.ebi.ac.uk/metabolights/MTBLS719</a>.</p> <p> </p> <p>1. Lovestone, S. <em>et al.</em> AddNeuroMed - The european collaboration for the discovery of novel biomarkers for alzheimer’s disease. in <em>Annals of the New York Academy of Sciences</em> (2009). doi:10.1111/j.1749-6632.2009.05064.x</p> <p>2. Lewis, M. R. <em>et al.</em> Development and Application of UPLC-ToF MS for Precision Large Scale Urinary Metabolic Phenotyping. <em>Anal. Chem.</em> <strong>88</strong>, acs.analchem.6b01481 (2016).</p> <p>3. Birkenbihl, C. <em>et al.</em> ANMerge: A comprehensive and accessible Alzheimer’s disease patient-level dataset. <em>medRxiv</em> (2020). doi:10.1101/2020.08.04.20168229</p>
Data from: Variations in regional white matter volumetry and microstructure during the post-adolescence period: a cross-sectional study of a cohort of 1,713 university students
<p>Human brain white matter undergoes a protracted maturation that continues well into adulthood. Recent advances in diffusion-weighted imaging (DWI) methods allow detailed characterisations of the microstructural architecture of white matter, and they are increasingly utilised to study white matter changes during development and ageing. However, relatively little is known about the late maturational changes in the microstructural architecture of white matter during post-adolescence. Here we report on regional changes in white matter volume and microstructure in young adults undergoing university-level education. As part of the MRi-Share multi-modal brain MRI database, multi-shell, high angular resolution DWI data were acquired in a unique sample of 1,713 university students aged 18 to 26. We assessed the age and sex dependence of diffusion metrics derived from diffusion tensor imaging (DTI) and neurite orientation dispersion and density imaging (NODDI) in the white matter regions as defined itein the John Hopkins University (JHU) white matter labels atlas. We demonstrate that while regional white matter volume is relatively stable over the age range of our sample, the white matter microstructural properties show clear age-related variations. Globally, it is characterised by a robust increase in neurite density index (NDI), and to a lesser extent, orientation dispersion index (ODI). These changes are accompanied by a decrease in diffusivity. In contrast, there is minimal age-related variation in fractional anisotropy. There are regional variations in these microstructural changes: some tracts, most notably cingulum bundles, show a strong age-related increase in NDI coupled with decreases in radial and mean diffusivity, while others, mainly cortico-spinal projection tracts, primarily show an ODI increase and axial diffusivity decrease. These age-related variations are not different between males and females, but males show higher NDI and ODI and lower diffusivity than females across many tracts. These findings emphasize the complexity of changes in white matter structure occurring in this critical period of late maturation in early adulthood.</p>
The CHASING COVID Cohort Study: A national, community-based prospective cohort study of SARS-CoV-2 pandemic outcomes in the USA
<p>The Communities, Households and SARS-CoV-2 Epidemiology (CHASING) COVID Cohort Study is a community-based prospective cohort study launched during the upswing of the USA COVID-19 epidemic. The objectives of the cohort study are to: (1) estimate and evaluate determinants of the incidence of SARS-CoV-2 infection, disease and deaths; (2) assess the impact of the pandemic on psychosocial and economic outcomes and (3) assess the uptake of pandemic mitigation strategies. 6740 people are enrolled in the cohort, including participants from all 50 US states, the District of Columbia, Puerto Rico and Guam. Participants are contacted regularly to complete study assessments, including interviews and dried blood spot specimen collection for serologic testing.</p> <p>Datasets are provided in CSV and sas7bdat (with formatting script) file formats.</p>
Dataset from: Leveraging open tools to realize the potential of self-archiving: A cohort study in clinical trials
<p>This record includes the data associated with the study "Leveraging open tools to increase the potential of self-archiving to increase discoverability: A cohort study in clinical trials". The code used to generate these data is available under an open license in GitHub (<a href="https://github.com/delwen/oa-archiving-permissions">https://github.com/delwen/oa-archiving-permissions</a>). The deposit includes:</p> <p>- `intovalue.csv`: download of the IntoValue dataset (IntoValue 1 and IntoValue 2), which is actively maintained in GitHub (<a href="https://github.com/maia-sh/intovalue-data">https://github.com/maia-sh/intovalue-data</a>). The data was downloaded on 17 December 2022. More information on the generation of this dataset can be found at: <a href="https://doi.org/10.5281/zenodo.5141343">https://doi.org/10.5281/zenodo.5141343</a>. This data corresponds to the start of the trial screening flow diagram in the manuscript (n = 3,788).</p> <p>- `oa-unpaywall.csv`: dataset containing the results of the Unpaywall API query (query date: 17 December 2022). The dataset queried includes the following adaptations from `intovalue.csv`:</p> <ul> <li>As updated registry data had been downloaded on 1 November 2022, the IntoValue inclusion criteria were re-applied: <ul> <li>Interventional</li> <li>Study completion date between 2009 and 2017</li> <li>Complete based on study status</li> <li>Conducted by a German university medical center.</li> </ul> </li> <li>The dataset was further limited to: <ul> <li>Unique trials (trials from IntoValue 2 were preserved)</li> <li>Unique publications with a DOI</li> </ul> </li> </ul> <p>- `oa-syp-permissions.csv`: dataset containing the results of the Shareyourpaper API query (query date: 17 December 2022). The dataset queried is the same as in `oa-unpaywall.csv`.</p> <p>- `oa-merged-data.csv`: dataset containing the merged Unpaywall and Shareyourpaper data for all clinical trial results publications considered in this study. The dataset was further limited to journal articles that resolved in Unpaywall and were published between 2010 - 2020 (based on the publication date in Unpaywall). This is the main dataset underlying the analyses in the manuscript.</p>
The effect of Vitamin D levels on the course of COVID-19 in hospitalized patients – a 1-year prospective cohort study
<p>Background: The aim of the current study was to assess the patients with COVID-19 and the impact of vitamin D supplementation on the course of COVID-19.<br> Methods: This prospective cohort study included patients hospitalized due to COVID-19 between December 2020 and December 2021. Patients' demographic, clinical, and laboratory parameters were analysed. <br> Results: 301 participants were enrolled in the study. 46 (15,3%) had moderate, and 162 (53,8%) had severe COVID-19. 14 (4,7%) patients died, and 30 (10,0%) were admitted to the ICU due to disease worsening. The majority needed oxygen therapy (n=224; 74,4%). Average vitamin 25(OH)D3 levels were below optimal at the admittance, and vitamin D deficiency was detected in 205 individuals. More male patients were suffering from vitamin D deficiency. Patients with the more severe disease showed lower levels of vitamin 25(OH)D3 in their blood. The most severe group of patients had more symptoms that lasted significantly longer with progressing disease severity. This group of patients also suffered from more deaths, ICU admissions, and treatments with dexamethasone, remdesivir, and oxygen.<br> Conclusion: Patients with the severe course of COVID-19 were shown to have increased inflammatory parameters, increased mortality, and higher incidence of vitamin D deficiency. The results suggest that the vitamin D deficiency might represent a significant risk factor for a severe course of COVID-19.</p> <p> </p>
Data and Codebook for: Post-recovery relapse of children treated with a simplified, combined nutrition treatment protocol in Mali : a prospective cohort study
<p>Data and Codebook to recreate analyses for the study. </p> <p>Abstract: The present study aimed to determine the 6-month incidence of relapse and associated factors among children who recovered following mid-upper arm circumference (MUAC) based simplified combined treatment using the ComPAS protocol. A prospective cohort of 420 children who had reached a MUAC ≥125 mm for two consecutive measures was monitored between December 2020 and October 2021. Children were seen at home by study enumerators fortnightly for 6 months. Relapse was defined as developing a MUAC <125 mm or edema. The overall 6-month cumulative incidence of relapse [95%CI] was 26.1% [21.7;30.8] and the incidence rate per 100 child-months was 4.8 [4.0;5.9]. Relapse was similar among children initially admitted to treatment with a MUAC<115mm or oedema and among those with a MUAC≥115mm but <125mm. Relapse was predicted by lower anthropometry both at admission to and discharge from treatment, and higher number of illness episodes per month of follow-up. Having a vaccination card, using an improved water source, having agriculture as the main source of income and increases in caregivers workload during follow-up all protected from relapse. Children discharged recovered following treatment remain at risk of relapsing into acute malnutrition. To achieve reduction in relapse, recovery criteria may need to be revised.</p>
Procedure of a cohort study
<p>Procedure of a cohort study for two arms/groups:</p> <p>One group is exposed, with a negative-impact risk factor (e.g., smoking, environmental exposure, etc.) or a preventive-impact factor (e.g., exercise, vaccination, diet, support, etc. ). The second group is non-exposed. Prospectively, the frequency with which participants in the two cohorts become ill or do not become ill (outcome) is determined. The risk of disease/non-disease is reported as an absolute frequency for both cohorts.</p>
The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort Study
ClinicalTrials.gov study NCT03835780. IPD Sharing: YES. Countries: 1. Publications: 2.
Data from: Variations in regional white matter volumetry and microstructure during the post-adolescence period: a cross-sectional study of a cohort of 1,713 university students
Open the record for dataset details and reuse information.
Effects of Tamoxifen on the Reproductive System of Females with Breast Cancer – an Ultrasound-based Cohort study
<p>This data represent an ultrasound-based cohort study conducted in three oncology centers. The studied groups included a total of ‎‎255 patients, 140 premenopausal (PreM) and 115 postmenopausal (PostM) female patients with ER-positive BC using TMX adjuvant hormonal treatment in ‎a dose of 20 mg/day for at least three months after surgery and adjuvant ‎chemo/radiotherapy.‎ The study conducted at the three main oncology centers in Baghdad. The collected data includes: age of the patient, menopausal status, co-morbid chronic illness such as hypertension, diabetes mellitus, etc, and used medications.an ultrasound-based cohort study conducted in three oncology centers. The studied groups included a total of ‎‎255 patients, 140 premenopausal (PreM) and 115 postmenopausal (PostM) female patients with ER-positive BC using TMX adjuvant hormonal treatment in ‎a dose of 20 mg/day for at least three months after surgery and adjuvant ‎chemo/radiotherapy.‎ The study conducted at the three main oncology centers in Baghdad. The collected data includes: age of the patient, menopausal status, co-morbid chronic illness such as hypertension, diabetes mellitus, etc, and used medications.</p>
Outcomes and adverse events of pre- and extensively drug-resistant tuberculosis patients in Kinshasa, Democratique Republic of the Congo: retrospective cohort study
<p><strong>Abstract</strong></p> <p><strong>Background</strong>: Extensively drug-resistant tuberculosis (XDR TB) is a very serious form of tuberculosis that is burdened with a heavy mortality toll, especially before the advent of new TB drugs. The Democratic Republic of the Congo (DRC) is among the countries most affected by this new epidemic.</p> <p><strong>Methods:</strong> A retrospective analysis was performed of the records of all patients with pre- and extensively drug-resistant tuberculosis hospitalized from January 1, 2015 to December 31, 2017 and monitored for at least 6 months to one year after the end of their treatment in Kinshasa; an individualized therapeutic regimen with bedaquiline for 20 months was built for each patient. The adverse effects were systematically monitored.</p> <p><strong>Results:</strong> Of the 40 laboratory-confirmed patients, 32 (80%) patients started treatment, including 29 preXRB and 3 XDR TB patients. In the eligible group, 3 patients (9.4%) had HIV-TB coinfections. The therapeutic success rate was 53.2%, and the mortality rate was 46.8% (15/32); there were no relapses, failures or losses to follow-up. All coinfected HIV–TB patients died during treatment. The cumulative patient survival rate was 62.5% at 3 months, 53.1% at 6 months and 53.1% at 20 months. The most common adverse events were vomiting, Skin rash, anemia and peripheral neuropathy.</p> <p><strong>Conclusion: </strong>Bedaquiline based treatment improves patient survival in the DRC despite the still high mortality rate. The new anti-tuberculosis<br> drugs are a real hope for the management of Drug Resistant tuberculosis patient and other new therapeutic combinations may improve favorable outcomes.</p>
Data from: One and two year visual outcomes from the Moorfields age-related macular degeneration database: a retrospective cohort study and an open science resource
Objectives: To analyse treatment outcomes and share clinical data from a large, single-center, well-curated database (8174 eyes / 6664 patients with 120,756 single entries) of patients with neovascular age related macular degeneration (AMD) treated with anti-vascular endothelial growth factor (VEGF). By making our depersonalised raw data openly available, we aim to stimulate further research in AMD, as well as setting a precedent for future work in this area. Setting: Retrospective, comparative, non-randomised electronic medical record (EMR) database cohort study of the UK Moorfields AMD database with data extracted between 2008 and 2018. Participants: Including one eye per patient, 3357 eyes/patients (61% female). Extraction criteria were ≥ 1 ranibizumab or aflibercept injection, entry of "AMD" in the diagnosis field of the EMR, and a minimum of one year of follow-up. Exclusion criteria were unknown date of first injection and treatment outside of routine clinical care at Moorfields before the first recorded injection in the database. Main outcome measures: Primary outcome measure was change in VA at one and two years from baseline as measured in Early Treatment Diabetic Retinopathy Study (ETDRS) letters. Secondary outcomes were the number of injections and predictive factors for VA gain. Results: Mean VA gain at one-year and two years were +5.5 (95%CI:5.0,6.0) and +4.9 (95%CI:4.2,5.6) letters respectively. Fifty-four percent of eyes gained ≥5 letters at two years, 63% had stable VA (±≤14 letters), forty-four percent of eyes maintained good VA (≥70 letters). Patients received a mean of 7.7 (95%CI:7.6,7.8) injections during year one and 13.0 (95%CI:12.8,13.2) injections over two years. Younger age, lower baseline VA, and more injections were associated with higher VA gain at two years. Conclusion: This study benchmarks high quality EMR study results of real life AMD treatment and promotes open science in clinical AMD research by making the underlying data publicly available.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.